Navigation Links
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Date:9/24/2008

ts travel in the circulatory system to the brain and muscles causing the nerves to become over-stimulated which leads to massive convulsions and death in severe cases.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

-- SparVax(TM) -- a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Third generation rPA anthrax vaccine

-- Valortim(R) -- a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) -- a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve

agents

-- RypVax(TM) -- a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit http://www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... MENLO PARK, Calif. , Aug. 27, 2014 ... developer of advanced cancer therapeutics , will be featured ... & Renshaw Global Investment Conference, sponsored by H.C. ... Tuesday, September 9th at 2:55 p.m. EDT in the ... Palace Hotel in New York City ...
(Date:8/27/2014)...  Decision Resources Group finds that physicians surveyed ... gastroenterology, endocrinology and nephrology) expect the robustness and ... been assessed in to be the strongest influencers ... Other key findings from the ... of Biosimilars Across Physician Specialties : ...
(Date:8/27/2014)... ISPE , the International Society for ... preview of its Drug Shortages Prevention Plan ... and maintain a robust and reliable supply of medications ... first for the industry, was developed by ISPE and ... how industry can best prevent drug shortages from occurring ...
Breaking Medicine Technology:DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 4
... Va., April 16 Insmed Inc. (Nasdaq:,INSM), a ... it has received approval from the United Kingdom,s ... the Company,s,first clinical study for a follow-on biologic ... form of human G-CSF, is a follow-on,biologic of ...
... Activity in a Variety of Tumor Types, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics for ... the presentation of preclinical results for two of ... given by EntreMed,scientists during two poster sessions at ...
Cached Medicine Technology:Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 2Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 4EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting 2EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting 3
(Date:8/28/2014)... 28, 2014 Registration is now open ... Warriors® in Holmdel, New Jersey on Sunday, October 19, ... the New Jersey Vietnam Veterans’ Memorial adjacent to the ... Bank Arts Center. All proceeds of the event will ... to restoring a sense of self, restoring the family ...
(Date:8/28/2014)... 2014 An unprecedented service that finds local ... 9 Spine offers their resources online and in person. ... a brick wall of discouragement as activities and hobbies are ... Cloud 9 Spine offers a refreshing plan of action. ... interaction that sets Cloud 9 Spine apart from other service ...
(Date:8/28/2014)... Alpine, NJ resident Othon Mourkakos is proud to ... Tiaras, to benefit the Immune Deficiency Foundation (IDF) Walk ... in Foley Square, New York. IDF is the ... (PI) are a group of more than 200 rare, ... immune system is missing or functions improperly. In ...
(Date:8/28/2014)... IL (PRWEB) August 28, 2014 The ... the healthcare industry from the time a patient books ... and insurance company provide final payments for services rendered ... based medical billing service has the RCM process ... software programs and computers become common place in nearly ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Aeroflow ... to acquire as part of a strategic expansion ... is positioned for taking ownership of new businesses ... increase economies of scale. , Last week, the ... with Hometown Respiratory to increase service in the ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Second Annual NJ Run 2Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2
... able to stop or even slightly improve the progression ... to implant // embryonic cells into their brains, say ... that helps control movement. People with Parkinson’s don’t produce ... in people with the condition. ,Researchers compared 20 ...
... of Pittsburgh Medical Center treated 33 prostate cancer patients, ... Patients received the same radiation doses that patients in ... study show the elderly patients had a five-year survival ... patients experienced no unusual or prolonged breaks in treatment ...
... to cancer-causing pollutants found in the air, report researchers ... .Past studies in mice have shown exposure to pollutants ... the fact the placenta filters out most of the ... in humans. ,Researchers collected blood samples from 265 ...
... United States suffer from erectile dysfunction. This causes a ... and weight loss // , obese men with erectile ... say researchers. ,Researchers, conducted a study to determine ... increase in physical activity, would improve obese men’s erectile ...
... not decrease, but may increase, the risk for dementia ... an association between postmenopausal estrogen use and lower risk ... estrogen plus progestin in women aged 65 to 79 ... estrogen-only trial, researchers found 47 participants were diagnosed with ...
... 20s could reduce the risk of developing high blood pressure ... with spikes in blood pressure are more likely to have ... ,Specialists say assessing blood pressure changes in response to stress ... risk of high blood pressure. In a large study more ...
Cached Medicine News:
Patient-Centered Therapy that promotes natural cardiac function....
The ACP 215 is the automated closed system cell processor with integrated process control....
... Durability for Excellent Access. Access ... challenging cases. PT² wires combine ... linear elastic nitinol distal core ... tip. This provides excellent access ...
... The PCS2 system ... for the collection of ... allow for the collection ... platelet-poor plasma, platelet-poor plasma ...
Medicine Products: